Professional Documents
Culture Documents
Morphine Pharmacokinetics in Children Following Cardiac Surgery
Morphine Pharmacokinetics in Children Following Cardiac Surgery
The pharmacokinetics of morphine have not been previously significantly slower clearance rates (0.73 + 0.3 L/kg/h) when
studied in children following cardiac surgery for tetralogy of compared to the rest of the patients (1.5 * 0.41 L/kg/h,
Fallot (TOF) or transposition of the great arteries (TGA). P < 0.05). Because most children needing inotropic support
Morphine steady-state pharmacokinetics were studied in 21 underwent the Fontan procedure, it is conceivable that their
children undergoing repair of TOF, TGA, or atrio-ventricular cardiovascular status had a major impact on morphine metab-
septal defects (AVSD). Children with TOF or TGA had in- olism. These results suggest a 50% reduction in morphine
creased right-sided pressures with no differences between dosage in children requiring inotropic support following
the groups. Children with TOF had significantly faster clear- cardiac surgery.
ance rates of morphine (1.39 f 0.37 L/kg/h) than children Copyright Q 1993 by W.B. Saunders Company
following the Fontan procedure (0.86 f 0.31 L/kg/h,
P < 0.01). When stratifying children by their postsurgical KEY WORDS: morphine, tetralogy of Fallot, transposition of
needs for inotropic support, those needing epinephrine, great arteries
dopamine, or dobutamine at more than 10 pg/kg/min had
Table 1. Comparison Between Children Following TOF and Table 3. Morphine Pharmacokinetics
Fontan Repair
Ke (h - 1) VD (L/kg) CL (L/kg/h) t%(h)
Fontan TOF
1 0.144 10.25 1.32 6.5
RA Morphine RA Morphine 2 0.102 13.1 1.28 11.5
Patient PWSSlre ClearalICe Patient PR?SSUW CleWSlC2
3 0.066 10.3 0.76 5.5
NO. (cm HzO) (L/kg/h) NO. (cm H,Ol (L/kg/h)
4 0.097 8.3 0.78 11.5
1 10 1.32 1 12 1.42 5 0.137 4.2 0.53 5.5
2 8 1.28 2 14 1.92 6 0.0589 20.6 1.42 6.5
3 17 0.50 3 14 1.03 7 0.0706 23.2 1.92 7
4 8 0.76 4 10 1.28 8 0.0531 14.8 1.03 3.3
5 8 0.78 5 14 1.06 9 0.134 10.9 1.28 3.3
6 14 0.72 6 13 1.16 0.096 ? 0.036 12.9 + 5.9 1.15 + 0.42 6.7 5 3
7 15 0.53 7 7 2.00
NOTE. Included in this table are only children in whom samples
8 14 0.96 8 14 1.24
during the elimination phase (after cessation of morphine infusion)
Mean 11.7 & 3.7 0.86* -t 0.31 12.3 + 2.6 1.39* + 0.37
were available.
*P < 0.01.
REFERENCES
1. Stanski DR. Greenblatt DJ, Lapas D, et al: Kinetics of 12. Robieux I. Kellner J, Copper M. et al: Analgesia in children
high-dose intravenous morphine in cardiac surgery patients. Clin with sickle cell crisis. Ped Hematol Oncol (in press)
Pharm Ther 30:629-635, 1981 13. Diagnostic Products Corporation, 5700 W 96th St, Los
2. Dahlstrom B, Bolme P, Feychting P, et al: Morphine kinetics Angeles, CA. 90045. Package Insert 1817. September 7, 1990
in children. Clin Pharm Ther 26:354-365, 1979
14. McRovie TI, Slattery JT. Lynn AM, et al: Maturation of
3. Dahlstrom B, Tamsen A. Paalzow L, et al: Patient-controlled
morphine clearance in newborns and infants. Clin Pharm Ther
analgesic therapy: IV pharmacokinetics and analgesic plasma
47: 132, 1990
concentrations of morphine. Clin Pharmacokinet 7:266-279, 1982
15. Jenkins JG. Lynn AM. Wood AE. et al: Acute hepatlc
4. Bhat R, Chari G. Gulati A, et al: Pharmacokinetics of a single
failure following cardiac operation in children. J Thorac Cardio-
dose of morphine in preterm infants during the first week of life. J
vast Surg 84:865-X71, 1982
Pediatr 117:477-481. 1990
5. McRovie Tl, Slattery JT, Lynn AM: Metabolism of morphine 16. Ball M, Moore RA, Fisher A. et al: Renal failure and the use
in early infancy. Pharmacotherapy 30:238-241,199O of morphine in intensive care. Lancet 1:784-786. 1985
6. Mercurio M. Nelli C, Gettner P, et al: Morphine pharmacoki- 17. Shelly M. Park GR: Renal failure and use of morphine m
netics in preterm newborns. Pediatr Res 25:71A. 1989 intensive care. Lancet 7:llUO. 1985
7. Chay PCW, Due BJ, Walker JS: Pharmacokinetic-pharmaco- 18. Hanks GW, Aherne GW: Morphine metabolism: Does the
dynamic relationships of morphine in neonates. Clin Pharm Ther renal hypothesis hold water? Lancet 1:221. 1985
11334-342. 1992
19. Notterman D. Greenwald B. Moran F. et al: Dopamine
8. Koren G, Butt W, Chinyanga H. et al: Postoperative mor-
clearance in critically ill infants and children: Effect of age and
phine infusion in newborn infants: Assessment of disposition
organ system dysfunction. Clin Pharm Ther 48:138-147, 1990
characteristics and safety. J Pediatr 107:963-967. 1985
20. Fennessy MR, Rattray JF: Cardiovascular ef?ects of intrave-
9. McGuinness GA, Farrington EA, Johnson GF, et al: Postop-
nous morphine in the anaesthetized rat. Eur J Pharm 14: l-8. 197 I
erative morphine requirement in newborn infants. Pediatric Res
25:224A, 1989 21. Rothbard RL. Schreiner BF, Yu NP: Hemodynamic and
10. Olkkola K, Mannuksela E, Korpela R, et al: Kinetics and respiratory effects of dezocine. ciramadol, and morphine. Clin
dynamics of postoperative intravenous morphine in children. Clin Pharm Ther 3X:84-88, 1985
Pharm Ther 44:128-136, 1988 22. Romagnoli A. Keats AS: Comparative hemodynamic effects
Il. Nahata M, Miser A, Miser J. et al: Variation in morphine of nalbuphine and morphine in patients with coronary artery
pharmacokinetics in children with cancer. Dev Pharmacol Ther disease. Cardiovascular Disease Bulletin of the Texas Heart
8:182-188, 1985 Institute 5:19-24. 1Y78